Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide in pediatric patients with type 2 diabetes mellitus
NCT02803918Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2017
- Primary completion
- Jan 2020
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Lixisenatide Arm with Placebo Arm (2 arms). Primary endpoints: Number of patients with adverse events at 10 weeks, Number of patients with treatment-emergent adverse events at 10 weeks and 1 more. Started May 2017; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02803918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02803918.